REPROCELL

Unlock the power of data with our secure and interactive AI analysis platform, developed in collaboration with IBM and STFC. Discover the genomic and clinical insights driving drug response, biomarker levels, and more. Our precision medicine AI platform empowers you to reveal data-rich insights with confidence: - Explore explainable AI results that meet industry standards - View quality control outcomes for assured prediction accuracy - Integrate with preclinical human tissue research to boost translational data reliability Take your research further and elevate your data's clinical impact. https://hubs.li/Q02VZkpK0 #DrugDiscovery #PrecisionMedicine #AIinHealthcare

When it comes to human iPSC lines, quality control (QC) is not just a checkbox—it's a fundamental part of your research journey. From mycoplasma testing to karyotyping, each step is vital for accurate results. Your research deserves the best practices! Our blog outlines the crucial QC tests necessary to validate your cell lines and ensure the reliability of your findings. 📊 📖 Dive into our blog: https://hubs.li/Q02VYTQb0 Visit our services page for comprehensive support in iPSC reprogramming and differentiation: https://hubs.li/Q02VYWr30

Boost your Cell Therapy Project with advanced gene editing! 🔬✨ 🧬REPROCELL’s StemEdit Service uses CRISPR-SNIPER for precise gene edits - knock-ins, knock-outs, SNPs - on iPSCs for clinical and research use. Repair mutations or modulate cell activity. Check out our visual guide to CRISPR-SNIPER gene editing below! 👇 Download this infographic as a PDF: https://hubs.li/Q02VPTKf0

Access global expertise through REPROCELL's network of accredited laboratories across the UK, US, India, and Japan. Our integrated approach ensures seamless coordination of your clinical research projects, providing you with consistent, high-quality results across multiple regions. Let us help you accelerate your drug discovery and development process with our comprehensive global reach and expertise. Learn more about how REPROCELL can support your research needs. https://hubs.li/Q02VgdpN0 #ClinicalResearch

In a recent study by Kwon et al. (2024), Matrixome's iMatrix-511 offered by REPROCELL was successfully used to culture iPSCs, which were then successfully differentiated into powerful NK cells enhancing cancer immunotherapy research. Xeno-free iMatrix-511 (recombinant Laminin-511 E8 fragments) offers a reliable, scalable solution for culturing various cell types, including iPSCs. Ready to elevate your in vitro cell culture experiments? Dive into the details below! Read the research paper: https://hubs.li/Q02Vnm_l0 Dive into our latest blog about NK cells derived from clinical iPSCs: https://hubs.li/Q02VnpBy0 Explore our iMatrix products: https://hubs.li/Q02VnnZp0 #CancerResearch #iPSCs #CellTherapy #Immunotherapy #NKCells #Innovation

By leveraging human tissue testing, researchers gain unique insights into how drug candidates will perform in human bodies. This approach enables the identification of drugs with a higher probability of success in clinical trials, ultimately leading to significant increases in clinical success rates for new treatments. At REPROCELL, we are committed to advancing drug discovery by providing data-rich, disease-relevant human tissue models that help de-risk clinical development, bridging the gap between preclinical and clinical stages. Learn more about how we're shaping the future of medicine. #DrugDiscovery #ClinicalTrials

🔬We have extensively validated our Clinical iPSC lines, generated with our StemRNA 5.0 Clinical Reprogramming Technology. As part of this process, we differentiated these iPSCs into a variety of cell types. For example, our clinical iPSC lines show efficient differentiation into Natural Killer (NK) Cells. ✍️ Find out more in our latest blog on clinical iPSC-derived NK cells (iNK cells): https://hubs.li/Q02TYW7X0 🌐 Explore our updated webpage: https://hubs.li/Q02TY_xs0 #CellularTherapy #RegenerativeMedicine #StemCells

🚀 Discover Our Latest Blog ✨ In a recent study, REPROCELL successfully derived Natural Killer (NK) cells from clinical StemRNA iPSCs in collaboration with the Tokyo Metropolitan Institute of Medical Science! These iPSC-derived NK cells show phenotypical and functional characteristics typical of primary NK cells, including cytotoxicity against the human chronic myeloid leukemia cell line - K562. This achievement not only highlights the incredible potential of allogeneic GMP-compliant iPSCs, but also marks a major leap forward in cancer immunotherapy. 🧠Curious to learn more? 👉 Read our new blog: https://hubs.li/Q02TX7xh0 🎥 Watch the incredible live video below where elongated iPSC-derived NK cells target and engulf the green CFSE-labelled K562 tumor cell line.

At REPROCELL USA, we've worked extensively with blood and blood components, including plasma and serum. Both biofluids are crucial in clinical and experimental research, but their differences matter. Plasma is collected with an anticoagulant, while serum is obtained after clotting—leading to variations in their metabolite and molecular contents. Our latest blog explores these differences, highlighting studies on metabolites, miRNAs, and their roles in liquid biopsies for cancer. Curious about which biofluid is best for your research? Read more to make an informed decision! https://hubs.li/Q02TMKbW0 #LifeSciences #Research #Metabolomics

📣 Reminder! Our webinar with Dr. Bruna Paulsen, Ph.D., is happening in a week's time! Join us on October 23rd to explore how REPROCELL’s clinical iPSCs are supporting Gameto’s revolutionary OSC-IVM technology for advancing reproductive health and infertility treatments.✨ 📅 Webinar Times: EMEA: 12:00 BST / 13:00 CEST USA/Canada: 12:00 EDT / 9:00 PDT ⏰ Spaces are filling up — register now! 🔗 https://hubs.li/Q02T25gX0